GLPwatch
Liraglutide-Induced Liver Injury: A Case Report and Review.
Case Rep Gastroenterol · 2025
Last updated 2026-08-28| Journal | Case Rep Gastroenterol, 2025 |
|---|---|
| Citations | 1 |
| Molecules | liraglutide |
Abstract
INTRODUCTION: Glucagon-like peptide-1 receptor agonists such as liraglutide have revolutionized the management of type 2 diabetes and obesity.
CASE PRESENTATION: We present a case of a 30-year-old woman who developed drug-induced liver injury (DILI) to liraglutide, confirmed on histology, with resolution on cessation of liraglutide over 6 months.
CONCLUSION: DILI secondary to liraglutide appears to be a rare but an important adverse effect.
Verbatim abstract via PubMed 41064547 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.